Evidence map›Paper›PMID 29334816›Full record

ArticleClinical toxicology (Philadelphia, Pa.)2018

Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study.

Michael Eddleston, Nicolas Fabresse, Adrian Thompson, Ibrahim Al Abdulla, Rachael Gregson, Tim King, Alain Astier, Frederic J Baud, R Eddie Clutton, Jean-Claude Alvarez

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical toxicology (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Ugly Side of Colchicine.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Michael Eddlestona Pharmacology, Toxicology, and Therapeutics , University/BHF Centre for Cardiovascular Science, University of Edinburgh , Edinburgh , UK.ORCID 0000-0002-6857-3441
Nicolas Fabressec Laboratoire de Pharmacologie - Toxicologie , Centre Hospitalier Universitaire Raymond Poincaré, AP-HP et MassSpecLab, Plateforme de Spectrométrie de Masse, Inserm U-1173, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin , Garches , France.
Adrian Thompsona Pharmacology, Toxicology, and Therapeutics , University/BHF Centre for Cardiovascular Science, University of Edinburgh , Edinburgh , UK.
Ibrahim Al Abdullad Micropharm Ltd , Newcastle Emlyn , UK.
Rachael Gregsonb Wellcome Trust Critical Care for Large Animals, Royal (Dick) School of Veterinary Studies and the Roslin Institute, University of Edinburgh , Edinburgh , UK.
Tim Kingb Wellcome Trust Critical Care for Large Animals, Royal (Dick) School of Veterinary Studies and the Roslin Institute, University of Edinburgh , Edinburgh , UK.
Alain Astiere School of Medicine Paris 12 , Paris , France.
Frederic J Baudf University Paris Diderot, Assistance Publique - Hopitaux de Paris , Paris , France.
R Eddie Cluttonb Wellcome Trust Critical Care for Large Animals, Royal (Dick) School of Veterinary Studies and the Roslin Institute, University of Edinburgh , Edinburgh , UK.
Jean-Claude Alvarezc Laboratoire de Pharmacologie - Toxicologie , Centre Hospitalier Universitaire Raymond Poincaré, AP-HP et MassSpecLab, Plateforme de Spectrométrie de Masse, Inserm U-1173, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin , Garches , France.
Roslin Institute · GBInserm · FRDélégation Paris 7 · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColchicine poisoning is commonly lethal. Colchicine-specific Fab fragments increase rat urinary colchicine clearance and have been associated with a good outcome in one patient. We aimed to develop a porcine model of colchicine toxicity to study the pharmacokinetics and efficacy of ovine Fab.

methodsA Göttingen minipig critical care model was established and serial blood samples taken for colchicine and Fab pharmacokinetics, clinical chemistry, and haematology. Animals were euthanised when the mean arterial pressure fell below 45 mmHg without response to vasopressor, or at study completion.

resultsInitial studies indicated that oral dosing produced variable pharmacokinetics and time-to-euthanasia. By contrast, intravenous infusion of 0.25 mg/kg colchicine over 1 h produced reproducible pharmacokinetics (AUC

conclusionsColchicine-specific Fab given early, in equimolar dose, bound colchicine, eliciting its movement into the blood, and preventing severe toxicity. Clinical studies are now needed to determine how soon this antidote must be given to work in human poisoning.

Indexed as

Administration, IntravenousAdministration, OralAnimalsAntidotesColchicineImmunoglobulin Fab FragmentsModels, AnimalSwineSwine, MiniatureAntidotesColchicineImmunoglobulin Fab FragmentsantidoteColchicinefab fragments

Identifiers

PMID29334816
PMCPMC6021765
OpenAlexW2784199748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.